Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $116000.0.

  • 4D Molecular Therapeutics' Cash from Financing Activities fell 7957.75% to $116000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year decrease of 9457.14%. This contributed to the annual value of $337.2 million for FY2024, which is 11503.9% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Cash from Financing Activities of $116000.0 as of Q3 2025, which was down 7957.75% from $601000.0 recorded in Q4 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Cash from Financing Activities peaked at $318.8 million during Q1 2024, and registered a low of -$847000.0 during Q1 2021.
  • Its 5-year average for Cash from Financing Activities is $36.2 million, with a median of $2.0 million in 2021.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 11773.78% in 2021, then skyrocketed by 26113800.0% in 2023.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Cash from Financing Activities stood at $116.1 million in 2021, then plummeted by 98.24% to $2.0 million in 2022, then skyrocketed by 132.75% to $4.8 million in 2023, then crashed by 87.38% to $601000.0 in 2024, then tumbled by 80.7% to $116000.0 in 2025.
  • Its Cash from Financing Activities was $116000.0 in Q3 2025, compared to $601000.0 in Q4 2024 and $568000.0 in Q3 2024.